Investing.com – Mizuho raised its price target on Spyre Therapeutics shares (NASDAQ:SYRE) to $84 from $53 while maintaining an Outperform rating. The stock surged to $63.18, up from a previous close of $51.77, reflecting investor enthusiasm following the trial results. The biotech has delivered a remarkable 320% return over the past year. The price target […]
Hot this week
Entertainment
Apple TV releases 'Unconditional' drama series trailer
Apple TV released a trailer for the new much-anticipated...
Business
Luria: A Jerusalem-inspired project with modern boutique design
In recent years, Jerusalem has gradually returned to the...
Health
The war may be over, but the stress remains and it is dangerous
In the period after the fighting, when the sirens...
World News
Hospital Margins Squeeze as Costs Outpace Revenue Growth
Hospitals’ financial positioning is somewhat stable but still under...
Topics
Advertisement
Related Articles
Advertisement
